Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa

Next Previous
Trial Profile

Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 257049 (Primary) ; AS01B; Hib-DTP-hepatitis B vaccine; Meningococcal vaccine group C conjugate; Poliovirus vaccine live oral; Rabies vaccine
  • Indications Diphtheria; Falciparum malaria; Haemophilus infections; Hepatitis B; Malaria; Meningococcal group C infections; Pertussis; Pneumonia; Poliomyelitis; Rabies; Tetanus
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK

    • Most Recent Events

    • 28 Jul 2022 Results published in the Journal of Infectious Diseases
    • 24 Dec 2020 Results of a analysis assessing the whether RTS,S/AS01(E) elicits antigen-specific serum IgA antibodies to the vaccine and other malaria antigens published in the Vaccine
    • 07 Nov 2019 Results evaluating safety and immunogenicity of RTS,S/AS01 in HIV-infected children published in the Vaccine
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top